Freshfields advises Roivant on sale of Telavant to Roche for $7.1 billion in cash and a near-term milestone payment of $150 million in cash

[ad_1] News 25 October 2023 Freshfields is advising Roivant Sciences Ltd. (Nasdaq: ROIV) on the sale of Telavant, a Roivant company owned by Roivant and Pfizer, to Roche for…

Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion

[ad_1] Updated Oct. 23, 2023 6:55 am ET Roche Holding has agreed to buy the developer of a bowel-disease treatment from Roivant Sciences, a company started by Republican presidential candidate…

Collecting Pharma’s Scraps Can Pay Off for This Biotech

[ad_1] Markets Heard on the Street Roivant has built a unique model that allows it to benefit from big pharma’s need to reduce R&D spending [ad_2] Source link